Enzymatic Discovery of a HER-2/neu Epitope That Generates Cross-Reactive T Cells

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Immunology

• Publication date

  2013-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.1201264PMID 23180824PMCID PMC3529812
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Secreted HLA recapitulates the immunopeptidome and allows in-depth coverage of HLA A*02:01 ligands.

  2012cited by this paper
• A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer

  2012cited by this paper
• Determining optimal cytotoxic activity of human Her2neu specific CD8 T cells by comparing the Cr51 release assay to the xCELLigence system.

  2012cited by this paper
• Clinical trial results of the HER‐2/neu (E75) vaccine to prevent breast cancer recurrence in high‐risk patients

  2012influential reference
• HER‐2 pulsed dendritic cell vaccine can eliminate HER‐2 expression and impact ductal carcinoma in situ

  2012cited by this paper
• CTL recognition of a novel HLA-A*0201-binding peptide derived from glioblastoma multiforme tumor cells

  2011cited by this paper
• TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype.

  2011cited by this paper
• The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed.

  2011cited by this paper
• A Single Autoimmune T Cell Receptor Recognizes More Than a Million Different Peptides*

  2011cited by this paper
• Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines

  2011cited by this paper
• Cancer and Leukemia Group B

  2010cited by this paper
• CD8 Controls T Cell Cross-Reactivity

  2010cited by this paper
• T cell receptor cross-reactivity directed by antigen-dependent tuning of peptide-MHC molecular flexibility.

  2009cited by this paper
• The multiple mechanisms of T cell receptor cross-reactivity.

  2009cited by this paper
• Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.

  2009cited by this paper
• Derivation of an amino acid similarity matrix for peptide:MHC binding and its application as a Bayesian prior

  2009influential reference
• HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice

  2009cited by this paper
• Proteases in MHC Class I Presentation and Cross-Presentation

  2009cited by this paper
• The E75 HER2/neu peptide vaccine

  2008influential reference
• Amino Acid Similarity Accounts for T Cell Cross-Reactivity and for “Holes” in the T Cell Repertoire

  2008cited by this paper
• Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy

  2007cited by this paper
• LMP2-specific inhibitors: chemical genetic tools for proteasome biology.

  2007cited by this paper
• The N-terminal Flanking Region of the TRP2360–368 Melanoma Antigen Determines Proteasome Activator PA28 Requirement for Epitope Liberation*

  2007cited by this paper
• Trastuzumab--mechanism of action and use in clinical practice.

  2007cited by this paper
• Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion.

  2007cited by this paper
• Pillars Article: Allele-Specific Motifs Revealed by Sequencing of Self-Peptides Eluted from MHC Molecules. Nature 1991. 351: 290–296.

  2006cited by this paper
• Destructive Cleavage of Antigenic Peptides Either by the Immunoproteasome or by the Standard Proteasome Results in Differential Antigen Presentation1

  2006cited by this paper
• Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. 1991.

  2006cited by this paper
• Increased Immunogenicity of an Anchor-Modified Tumor-Associated Antigen Is Due to the Enhanced Stability of the Peptide/MHC Complex: Implications for Vaccine Design1

  2005cited by this paper
• Proteasome and peptidase function in MHC-class-I-mediated antigen presentation.

  2004cited by this paper
• Antigenicity and immunogenicity of peptide analogues of a low affinity peptide of the human telomerase reverse transcriptase tumor antigen

  2004cited by this paper
• HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway

  2004cited by this paper
• Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice.

  2003cited by this paper
• Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach.

  2003cited by this paper
• Natural history of more than 20 years of node-positive primary breast carcinoma treated with cyclophosphamide, methotrexate, and fluorouracil-based adjuvant chemotherapy: a study by the Cancer and Leukemia Group B.

  2003cited by this paper
• Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules

  2003influential reference
• Relationship between kinetic stability and immunogenicity of HLA‐DR4/peptide complexes

  2002cited by this paper
• Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.

  2002cited by this paper
• Cross‐reactivity in T‐cell antigen recognition

  2001cited by this paper
• Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients.

  2001cited by this paper
• Role of HER2 gene overexpression in breast carcinoma

  2000cited by this paper
• SYFPEITHI: database for MHC ligands and peptide motifs

  1999cited by this paper
• Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas.

  1999cited by this paper
• Modulation of Proteasomal Activity Required for the Generation of a Cytotoxic T Lymphocyte–defined Peptide Derived from the Tumor Antigen MAGE-3

  1999cited by this paper
• Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors.

  1998cited by this paper
• Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8.

  1997cited by this paper
• Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability.

  1996cited by this paper
• Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines

  1995cited by this paper
• Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide.

  1995cited by this paper
• The “Working Group”

  1994cited by this paper
• In vitro generation of human cytolytic T-cells specific for peptides derived from the HER-2/neu protooncogene protein.

  1994cited by this paper
• Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids.

  1993cited by this paper
• Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides.

  1993cited by this paper
• Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules

  1991cited by this paper

• Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy

  2020cites this paper
• Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity

  2020cites this paper
• Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1

  2019cites this paper
• Evaluation of Newcastle disease virus mediated dendritic cell activation and cross‐priming tumor‐specific immune responses ex vivo

  2019cites this paper
• Metformin as an archetype immuno-metabolic adjuvant for cancer immunotherapy

  2019cites this paper
• Treating cancer with engineered T cell therapies: Murine and canine models of safety and efficacy

  2016cites this paper
• A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu–Expressing Tumor in HLA-A2 Transgenic Mice

  2016cites this paper
• A therapeutic Her 2 / neu vaccine targeting dendritic cells preferentially inhibits the growth of low Her 2 / neu-expressing tumor in HLA-A 2 transgenic mice

  2016cites this paper
• A Human ErbB2-Specific T-Cell Receptor Confers Potent Antitumor Effector Functions in Genetically Engineered Primary Cytotoxic Lymphocytes

  2014influential citation
• CD 47 in the tumor microenvironment limits cooperation between anti-tumor T cell immunity and radiation therapy

  2014cites this paper
• CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.

  2014cites this paper
• The two sides of HER2/neu: immune escape versus surveillance.

  2013cites this paper